BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Saturday, December 27, 2025
Home » Authors » Aaron Lorenzo

Articles by Aaron Lorenzo

FDA Advisers Oppose Wider Label For Factive In Sinusitis

Sep. 13, 2006
By Aaron Lorenzo
GAITHERSBURG, Md. - The FDA's Anti-Infective Drugs Advisory Committee voted against expanding the label for Factive (gemifloxacin) to include acute bacterial sinusitis, absent an additional study to demonstrate its superiority. (BioWorld Today)
Read More

FDA Advisors Meet On Factive's Rash Risks

Sep. 12, 2006
By Aaron Lorenzo

FDA Advisors Meet On Factive's Rash Risks

Sep. 12, 2006
By Aaron Lorenzo

Report Hints That PDUFA Costs Expected To Rise

Sep. 11, 2006
By Aaron Lorenzo

Report Hints That PDUFA Costs Expected To Rise

Sep. 11, 2006
By Aaron Lorenzo

ODAC: Study Required To Expand Abraxane's Label

Sep. 8, 2006
By Aaron Lorenzo
SILVER SPRING, Md. - The FDA's Oncology Drugs Advisory Committee on Thursday disagreed with a shortened approval pathway for Abraxane (paclitaxel) as an adjuvant breast cancer treatment, which would expand its label. (BioWorld Today)
Read More

ODAC: Study Required To Expand Abraxane's Label

Sep. 8, 2006
By Aaron Lorenzo
SILVER SPRING, Md. - The FDA's Oncology Drugs Advisory Committee on Thursday disagreed with a shortened approval pathway for Abraxane (paclitaxel) as an adjuvant breast cancer treatment, which would expand its label. (BioWorld Today)
Read More

Genta's Stock Slides Again As ODAC Turns Back Genasense

Sep. 7, 2006
By Aaron Lorenzo
SILVER SPRING, Md. - The FDA's Oncology Drugs Advisory Committee on Wednesday rejected Genta Inc.'s new drug application for Genasense (oblimersen sodium) to treat relapsed or refractory chronic lymphocytic leukemia, driving down the company's stock value for a second consecutive day. (BioWorld Today)
Read More

Genta's Stock Slides Again As ODAC Turns Back Genasense

Sep. 7, 2006
By Aaron Lorenzo
SILVER SPRING, Md. - The FDA's Oncology Drugs Advisory Committee on Wednesday rejected Genta Inc.'s new drug application for Genasense (oblimersen sodium) to treat relapsed or refractory chronic lymphocytic leukemia, driving down the company's stock value for a second consecutive day. (BioWorld Today)
Read More

Auxilium, Oscient End Testim Pact; Auxilium Signing Lease

Sep. 6, 2006
By Aaron Lorenzo
Previous 1 2 … 33 34 35 36 37 38 39 40 41 … 237 238 Next

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for Dec. 24, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for Dec. 24, 2025.
  • Illustration of magnifying glass looking at cancer in the brain

    Researchers discover how glioblastoma tumors dodge chemotherapy

    BioWorld MedTech
    Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
  • Left: Anthony Fauci. Right: Transmission electron micrograph of HIV-1 virus particles

    HIV research is close to a cure but far from ending the pandemic

    BioWorld
    Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
  • Illustration of tau accumulating in a neuron cell.

    ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug

    BioWorld
    ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • NME Digest
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing